Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

ECB. 2022; 11(6): 74-81


SYNTHESIS, CHARACTERIZATION, MOLECULAR DOCKING OF SULPHANILAMIDE SCHIFF BASE METAL COMPLEXES AND ITS ANTIBACTERIAL, ANTI-INFLAMMATORY AND ANTI DEPRESSANT ACTIVITY

Mugdivari Sangeetha, R.Gandhimathi.




Abstract

In our study we have a tendency to synthesized schiff’ base of bactericide drug sulphanilamide on treating with
aromatic aldehydes like p-diethyl amino benzyldehyde and p-dimethyl amino benzyldehyde. The synthesized schiff’s bases
were regenerate to its ion Schiff bases by treating with methyl group halide. The ion Schiff bases were regenerate to metal
complexes by treating with metals like CuCl2, ZnCl2 and CdCl2. All the synthesized compounds were characterised by
Elemental analysis, IR and 1H proton magnetic resonance. Docking study was performed to know the interaction of binding
sites with protein receptor using MAO-B enzymes (PDB ID: 2BK5) and COX-2 enzyme (PDB ID: 5IKR) by Virtual
Screening software for Computational Drug Discovery. Synthesized metal complexes were evaluated for antibacterial, anti
inflammatory and antidepressant activity. Copper metal complexes showed potent antibacterial and anti-inflammatory
activity. Significant anti-depressant activity was shown for 1A2 and 1B2 zinc metal complexes.

Key words: Sulphanilamide, antibacterial, anti-inflammatory, antidepressant activity






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.